trial · primary record
Nivolumab and Relatlimab
Metastatic Melanoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2030-12 |
| Primary endpoint | Incidence and Severity of Dose Limiting Toxicities (DLTs) |
| Registry ID | NCT07281924 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:14.024Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07281924
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.